-
News On Bispecific Antibodies
M802 bispecific antibody binds to a tumor target and an immune target simultaneously to recognize and link cancer cells and immune cells, subsequently forms an effective tumor-immune cell complex in c
2017/12/21 66
-
First CAR-T approved on market: Novartis Priced Kymriah $475,000
August 31, 2017, Novartis announced that the United States FDA has approved its CAR-T therapy Tisagenlecleucel (formerly known as CTL019) listed for the treatment of B cell precursor acute lymphoblast
2017/10/27 28
